<SEC-DOCUMENT>0001193125-18-077351.txt : 20180309
<SEC-HEADER>0001193125-18-077351.hdr.sgml : 20180309
<ACCEPTANCE-DATETIME>20180309161556
ACCESSION NUMBER:		0001193125-18-077351
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180308
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180309
DATE AS OF CHANGE:		20180309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COOPER COMPANIES INC
		CENTRAL INDEX KEY:			0000711404
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				942657368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08597
		FILM NUMBER:		18680236

	BUSINESS ADDRESS:	
		STREET 1:		6140 STONERIDGE MALL RD
		STREET 2:		STE 590
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588
		BUSINESS PHONE:		9254603600

	MAIL ADDRESS:	
		STREET 1:		6140 STONERIDGE MALL ROAD
		STREET 2:		SUITE 590
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COOPERVISION INC
		DATE OF NAME CHANGE:	19870701
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d488600d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;8, 2018 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THE COOPER COMPANIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">1-8597</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-2657368</FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including Zip Code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(925) <FONT STYLE="white-space:nowrap">460-3600</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of
this chapter). </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Emerging Growth Company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financing accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2018, The Cooper Companies, Inc. (the &#147;Company&#148;) announced that
its Board of Directors (its &#147;Board&#148;) has named Albert G. White III as the President and Chief Executive Officer (&#147;CEO&#148;) of the Company, effective May&nbsp;1, 2018. Mr.&nbsp;White will succeed Robert S. Weiss, who will retire as
President and CEO, effective April&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;White, 49, has served as Chief Financial Officer since November 2016. He also serves as
Executive Vice President and Chief Strategy Officer, positions he has held since December 2015 and July 2011, respectively. Since August 2015, Mr.&nbsp;White also oversees and directs our women&#146;s healthcare business and is currently CEO of
Cooper Medical, Inc., the parent company to CooperSurgical, Inc. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to
joining the Company, Mr.&nbsp;White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;White&#146;s current compensation is set forth in the Company&#146;s proxy statement filed with the Securities Exchange Commission on
February&nbsp;2, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM 7.01. Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 8, 2018, the Company issued a press release announcing the appointment of Mr. White and the retirement of Mr. Weiss. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference. Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, will not be deemed &#147;filed&#148; for the purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the
Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report on Form 8-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM 9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d488600dex991.htm">Press Release dated March 8, 2018, of The Cooper Companies, Inc.</A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">THE COOPER COMPANIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March&nbsp;9, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Albert G. White, III<U> </U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Albert G. White, III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and Chief Strategy Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d488600dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1%">


<IMG SRC="g488600g0309123455762.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 8, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Albert
White to Succeed Robert Weiss as CEO of the Cooper Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Weiss to Retire; Remain on Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASANTON, Calif., March</B><B></B><B>&nbsp;8, 2018</B> &#150; The Cooper Companies, Inc. (NYSE: COO) today announced that its Board of Directors has named
Albert G. White III President and Chief Executive Officer of The Cooper Companies effective May&nbsp;1, 2018. Mr.&nbsp;White will succeed Robert S. Weiss who will retire as President and Chief Executive Officer on April&nbsp;30, 2018, and then act
in an advisory capacity until December&nbsp;31, 2018, to ensure a smooth transition. Mr.&nbsp;White has held a number of senior management roles in the Company including most recently Executive Vice President, Chief Financial Officer, Chief Strategy
Officer and CEO of Cooper Medical, Inc., the holding company for CooperSurgical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the transition, A. Thomas Bender, Chairman of the
Company&#146;s Board, said, &#147;On behalf of the Board, we thank Bob for his leadership and accomplishments for the last 40 plus years, and in particular his stewardship of Cooper over the last 10 plus years as CEO. Through his leadership, the
Company has grown to over $12&nbsp;billion in market value, built strong franchises and organizations in its CooperVision and CooperSurgical businesses and become a member of the S&amp;P 500. Bob joined Cooper in 1977 and has held many senior
management positions within the Company including Chief Operating Officer, Chief Financial Officer and President of CooperVision. Notably, his continued commitment to succession planning culminated in the decision to name Al as the next CEO. We are
all highly confident in Al&#146;s ability to lead Cooper&#146;s growth and he has the full support of the Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Al joined Cooper in
2006 and has helped lead and execute many of the Company&#146;s investments and strategic decisions. Commenting on the news, he noted &#147;Bob&#146;s dedication, leadership and contributions to Cooper have been exceptional, and he has positioned us
well for continued growth in both our vision and women&#146;s healthcare businesses. Our financial strength, global reach and innovative products and services are a proud legacy for Bob and a strong foundation for the future of Cooper. I am
privileged and very excited to lead the organization going forward.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This is the perfect time for Al to become Cooper&#146;s next CEO. He is a
very strong leader and I am confident he will continue driving Cooper&#146;s success.&#148; said Mr.&nbsp;Weiss. &#147;Serving as President and CEO of Cooper has been a privilege and I would like to thank all our employees for their commitment and
dedication. It has been an honor to lead such an outstanding organization, and I look forward to continuing to serve on the Board.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The
Cooper Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cooper Companies, Inc. (&#147;Cooper&#148;) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is
dedicated to being A Quality of Life Company&#153; with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a
commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and
services focusing on women&#146;s health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has more than 11,000 employees with products sold in over 100 countries. For more information, please visit <U>www.coopercos.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995.&nbsp;Statements relating
to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2018 Guidance and all statements regarding acquisitions including the
acquired companies&#146; financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as
estimates of our and the acquired entities&#146; future expenses, sales and diluted earnings per share are forward looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls,
anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking.&nbsp;To identify these statements look for words like &#147;believes,&#148; &#147;expects,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;seeks,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;estimates&#148; or &#147;anticipates&#148; and similar words or phrases.&nbsp;Forward-looking statements
necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among the factors that
could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions, including the impact of
continuing uncertainty and instability of certain countries that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items, including but not limited to, the United
Kingdom&#146;s election to withdraw from the European Union; changes in tax laws or their interpretation and changes in statutory tax rates, including but not limited to, United States and other countries with proposed changes to tax laws, some of
which may affect our taxation of earnings recognized in foreign jurisdictions and/or negatively impact our effective tax rate; our existing indebtedness and associated interest expense, most of which is variable and impacted by rate increases, which
could adversely affect our financial health or limit our ability to borrow additional funds; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that
would decrease our revenues and earnings; acquisition-related adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to
record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that
are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the
acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw
material supply chain due to integration of acquisitions, natural disasters, system upgrades or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution
facilities due to technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; disruptions in supplies of raw materials, particularly components used to
manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting
the health care industry including the contact lens industry specifically and the medical device or pharmaceutical industries generally; compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations
pertaining to privacy and security of third party information, such as HIPAA in the U.S. and the pending General Data Protection Regulation requirements which are to take effect in Europe on May&nbsp;25, 2018, including but not limited to those
resulting from data security breaches; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement or other litigation; limitations on
sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, technological advances by competitors, new products and patents attained by competitors, and competitors&#146; expansion through acquisitions; reduced sales, loss of customers and costs and
expenses related to product recalls and warning letters; failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third
party payors for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, and idle manufacturing facilities and equipment; the success
of our research and development activities and other <FONT STYLE="white-space:nowrap">start-up</FONT> projects; dilution to earnings per share from acquisitions or issuing stock; changes in accounting principles or estimates; environmental risks;
and other events described in our Securities and Exchange Commission filings, including the &#147;Business&#148; and &#147;Risk Factors&#148; sections in the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for
the fiscal year ended October&nbsp;31, 2017, as such Risk Factors may be updated in quarterly filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We caution investors that forward-looking
statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COO-G </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: The Cooper Companies, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kim Duncan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cooper Companies, Inc. <U> </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@cooperco.com</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1%;margin-right:84%">


<IMG SRC="g488600g0309123455855.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: The Cooper Companies, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">News Provided by Acquire Media </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g488600g0309123455762.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g488600g0309123455762.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y (T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBFNZ1H
MSNP55&22< "@!:*\G\1?%B=]0.F>%+3[5+G'GE"^X_["CJ/<UG+:?%J^'VG[
M3-!GD1[T3_QVMUAY6O)I&+K*]DKGM)JF^J6"71M7NX5G&,QE_F&>G%>3:=XX
M\:Z'K=GIOB*Q+Q7$JQ!I8]IY/4,O#5V_B'39KG4[UH(7!>UM566->0PG8G!]
M0.:F5-Q=GU'&IS+0ZZEK@-37Q!;3R6T-W>"Q21]DS!Y)&;:NT93G&2WMFNST
MS[3_ &9;?;&W7/EKYI*[<MCGCM4.-E<M2N[%RBBBI*"BBB@ HHHH **** "B
MBB@!*\R^,'B">STRUT.S)$U^<R;>I0'  ^I_E7IM>.>.]LGQ@T".<_NP8 ,]
M/OYQ^=;8=)SUZ&-=M0T&W5U:?"S0[>PL((I_$EY&'FF9<^6#V'X\ =\9J.#P
MO\2]6@&I2:S+;RN-ZPO<LC8_W5X7Z4R]1+GX^K'?<QK.GEAN0<1@J/SYKVL5
MM.HX)=6]3.$%-M=$>1>&O&%]'K*^%O&]L))?,7R9IE!*/GY<GH0<<-76>/\
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<+^SG9N5@I=B!CH.O3VK6HHI7;!)(****!G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g488600g0309123455855.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g488600g0309123455855.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X )8# 2(  A$! Q$!_\0
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M49^7=ME&#QVX!HHI*;3&X)D'_",ZDMFSP:7<.WVM9(+:8P"-"$P6=%.U5/\
7LDL" >^*].%%%1.39<(I"T445!9__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
